These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 20033379)

  • 1. Vascular integrins: therapeutic and imaging targets of tumor angiogenesis.
    Rüegg C; Alghisi GC
    Recent Results Cancer Res; 2010; 180():83-101. PubMed ID: 20033379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
    Rüegg C; Dormond O; Mariotti A
    Biochim Biophys Acta; 2004 Mar; 1654(1):51-67. PubMed ID: 14984767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets.
    Alghisi GC; Rüegg C
    Endothelium; 2006; 13(2):113-35. PubMed ID: 16728329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?
    Rüegg C; Dormond O; Foletti A
    Endothelium; 2002; 9(3):151-60. PubMed ID: 12380640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
    Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
    Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radionuclide imaging of tumor angiogenesis.
    Dijkgraaf I; Boerman OC
    Cancer Biother Radiopharm; 2009 Dec; 24(6):637-47. PubMed ID: 20025543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
    Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis.
    Rüegg C; Mariotti A
    Cell Mol Life Sci; 2003 Jun; 60(6):1135-57. PubMed ID: 12861381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of integrins in tumor angiogenesis.
    Hwang R; Varner J
    Hematol Oncol Clin North Am; 2004 Oct; 18(5):991-1006, vii. PubMed ID: 15474331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrins in angiogenesis and lymphangiogenesis.
    Avraamides CJ; Garmy-Susini B; Varner JA
    Nat Rev Cancer; 2008 Aug; 8(8):604-17. PubMed ID: 18497750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biology of integrins.
    Stupack DG
    Oncology (Williston Park); 2007 Aug; 21(9 Suppl 3):6-12. PubMed ID: 17927025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
    Reinmuth N; Liu W; Ahmad SA; Fan F; Stoeltzing O; Parikh AA; Bucana CD; Gallick GE; Nickols MA; Westlin WF; Ellis LM
    Cancer Res; 2003 May; 63(9):2079-87. PubMed ID: 12727823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of endothelial cell integrin function and angiogenesis by COX-2, cAMP and Protein Kinase A.
    Dormond O; Rüegg C
    Thromb Haemost; 2003 Oct; 90(4):577-85. PubMed ID: 14515176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of integrins.
    Tucker GC
    Curr Opin Pharmacol; 2002 Aug; 2(4):394-402. PubMed ID: 12127872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide.
    Erdreich-Epstein A; Shimada H; Groshen S; Liu M; Metelitsa LS; Kim KS; Stins MF; Seeger RC; Durden DL
    Cancer Res; 2000 Feb; 60(3):712-21. PubMed ID: 10676658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors.
    Kerr JS; Wexler RS; Mousa SA; Robinson CS; Wexler EJ; Mohamed S; Voss ME; Devenny JJ; Czerniak PM; Gudzelak A; Slee AM
    Anticancer Res; 1999; 19(2A):959-68. PubMed ID: 10368639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrins as targets of angiogenesis inhibition.
    Westlin WF
    Cancer J; 2001; 7 Suppl 3():S139-43. PubMed ID: 11779085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A targeted approach for antiangiogenic therapy of metastatic human colon cancer.
    Ellis LM
    Am Surg; 2003 Jan; 69(1):3-10. PubMed ID: 12575772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumour angiogenesis inhibition by therapeutic monoclonal antibodies].
    Cézé N; Lecomte T; Watier H
    Med Sci (Paris); 2009 Dec; 25(12):1099-104. PubMed ID: 20035685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
    Wilkinson-Berka JL; Jones D; Taylor G; Jaworski K; Kelly DJ; Ludbrook SB; Willette RN; Kumar S; Gilbert RE
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.